VC · AI + Biology + HealthcareVenture Capital · AI + Biology + Healthcare
Jeffrey Low, MD
Investing at the intersection of AI, biology, and healthcare
Partner, Averin
Scout Partner, Sequoia Capital
Perspective
Featured Insights
View all →Latest
LinkedIn·
What Do Moderna, Snowflake and Livongo Have in Common?
Not the sector. Not the founders. A venture firm started each one before it had a product. Three ideas from my guest lecture in Stanford's CS 522 on how companies get built on purpose.
12.7K views · 136 engagements
Andreessen Horowitz·
16 Pitfalls to Avoid When Building a Computational Therapeutics Company
LinkedIn·
Biotech Is Crowding Into Consensus at the Wrong Moment
36.0K views · 713 engagements
Portfolio
Select Investments
View all →
Exscientia
AI-driven drug discovery platform combining precision design with automated experimentation.
IPO (NASDAQ: EXAI), merged with Recursion
“Jeffrey is the rare investor who understands both AI and drug discovery. He backed Exscientia early, helped shape our strategy, brought credibility to subsequent financings, and was a valuable partner through our IPO.”
Board Observer·Novo Holdings
Details▾
Erasca
Precision oncology company developing therapies targeting the RAS/MAPK pathway.
IPO (NASDAQ: ERAS)
“Jeffrey and my relationship spans many years, even before Erasca's launch. In the early days of the company's build, Jeffrey was ahead of the curve and was among the early investors to commit. This exemplifies Jeffrey's instinct for finding and backing exceptional teams rather than just following others.”
Investor·Andreessen Horowitz
Details▾
Freenome
Multiomics platform for early cancer detection through routine blood draws.
SPAC (NASDAQ: FRNM)
“I've known Jeffrey since Freenome was a five-person company. He helped lead our Series A, and over the years became one of the closest partners to me and the leadership team. When it mattered most, Jeffrey consistently stepped up well beyond what you'd expect from a typical investor.”
Board Observer·Andreessen Horowitz
Details▾Presence
Recent Appearances
View all →
Stanford CS 522: Seminar in AI in Healthcare
Company Creation in Life Sciences and Healthcare
Guest lecture on how venture firms build companies on purpose, from Kleiner Perkins incubating Genentech to Flagship creating Moderna. Why ownership drives venture returns, why health companies have to win inside reimbursement, regulation and clinical adoption rather than route around them, and how Averin starts from people, ideas or technology and runs every creation through six steps with a kill point at each. Plus case studies in Moderna, Allostery and xPharma, and the Averin Fellowship for students who want to help build the first version.
Speaking·
Read the recap
BFA New Frontier 2026
From Seed to IPO in Biotech
Two sessions at BFA Global Investors' annual US investor conference, both hosted by Jeff Pehl. A biotech fireside chat on why AI's real value lies in better biological and clinical bets rather than faster discovery, with clinical trial design as the nearest prize. Plus a main-track panel with Kristin Baker Spohn of BAM Corner Point on where AI is already paying off in healthcare.
Speaking·
TreeHub Founders Lunch
Company Creation and What Makes a Healthcare Founder Fundable
Fireside chat with founders in TreeHub's health-focused residency: Averin's company creation model, how capital gets metered from validation through launch, and where defensibility breaks for AI-native healthcare companies. Plus what earns conviction in a founding team.
Speaking·